Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MGd Clear all
Completed Phase 2 Interventional

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT00096837
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2006 · Synced Oct 26, 2026, 10:36 PM EDT
Recruiting Phase 4 Interventional

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

NCT07224529
View directory record Official record
Conditions
Meibomian Gland Dysfunction (MGD)
Interventions
Vevye(Cyclosporine 0.1% Ophthalmic Solution)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas

NCT00080054
View directory record Official record
Conditions
Glioma, Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Neoplasm
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT00305864
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
106
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 26, 2026, 10:36 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluating Impact of Systane iLux on Dryness Symptoms and Wearing Time in Contact Lens Users

NCT05306561
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
Systane iLux thermal pulsation treatment
Procedure
Lead sponsor
Periman Eye Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 26, 2026, 10:36 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

NCT06064071
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Disease
Interventions
Nordlys SWT IPL, Meibomian Gland Expression (MGX), Sham Nordlys SWT IPL
Device · Procedure
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida • Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 26, 2026, 10:36 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device

NCT03788486
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
2-3 Joule LED blue light device
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 26, 2026, 10:36 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Non-invasive Ocular Surface Measurements Before and After Interventions

NCT01228929
View directory record Official record
Conditions
Dry Eye Syndrome, Healthy
Interventions
Environmental Chamber Condition Change Intervention
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

NCT05454956
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
Interventions
TP-03, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Northridge, California • Kansas City, Missouri • Cary, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Phase 4 Interventional

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

NCT04413279
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
LipiFlow Thermal Pulsation, Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
Procedure · Drug
Lead sponsor
Eye Surgeons of Indiana
Network
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 26, 2026, 10:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction

NCT01979887
View directory record Official record
Conditions
Meibomian Glands
Interventions
Meibum Expression
Procedure
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation

NCT01128049
View directory record Official record
Conditions
Aqueous Deficient Dry Eye, Meibomium Gland Dysfunction
Interventions
Subjective Questionnaire, Measurement with wavefront sensor (right eye, then left eye), Instill Saline Drop
Behavioral · Procedure · Drug
Lead sponsor
University of Rochester
Other
Eligibility
20 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction

NCT03888378
View directory record Official record
Conditions
Meibomian Gland Dysfunction, MGD-Meibomian Gland Dysfunction
Interventions
0.3% Topical Minocycline Ointment, 1% Topical Minocycline Ointment, Topical Vehicle Ointment
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Azusa, California • Huntington Beach, California • Inglewood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

NCT00086034
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Diego, California • Stanford, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2007 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease

NCT03492541
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Propylene glycol-based eye drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Kansas City, Missouri • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the LipiFlow System With a New Activator

NCT04500821
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Activator LFD-2100
Device
Lead sponsor
Johnson & Johnson Surgical Vision, Inc.
Industry
Eligibility
22 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Bakersfield, California • Torrance, California • Hurst, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Not applicable Interventional Results available

Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery

NCT01808560
View directory record Official record
Conditions
Blepharitis, Dry Eye Syndrome
Interventions
LipiFlow Pre-Treatment, LipiFlow Post-treatment
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Hoffman Estates, Illinois • Lake Villa, Illinois • Winchester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 26, 2026, 10:36 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Treating Meibomian Gland Disease in a Pediatric Population

NCT07229001
View directory record Official record
Conditions
Dry Eye Disease, Meibomian Gland Disease
Interventions
Low level light treatment, warm compress and artificial tear
Other
Lead sponsor
Illinois College of Optometry
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 26, 2026, 10:36 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

NCT06542276
View directory record Official record
Conditions
MGD-Meibomian Gland Dysfunction
Interventions
Thermal Vectored Pulsation
Device
Lead sponsor
Dunes Eye Consultants
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dakota Dunes, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 26, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 26, 2026, 10:36 PM EDT